ACETAZOLAMIDE TABLET

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

ACETAZOLAMIDE

Διαθέσιμο από:

AA PHARMA INC

Φαρμακολογική κατηγορία (ATC):

S01EC01

INN (Διεθνής Όνομα):

ACETAZOLAMIDE

Δοσολογία:

250MG

Φαρμακοτεχνική μορφή:

TABLET

Σύνθεση:

ACETAZOLAMIDE 250MG

Οδός χορήγησης:

ORAL

Μονάδες σε πακέτο:

100/500

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

CARBONIC ANHYDRASE INHIBITORS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0107512001; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2010-06-24

Αρχείο Π.Χ.Π.

_Acetazolamide _
_Page 1 of 12_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACETAZOLAMIDE
Acetazolamide Tablets
Tablets, 250 mg, Oral
Carbonic Anhydrase Inhibitor
BP
AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Initial Authorization:
JUN 03, 2010
Date of Revision:
JAN 4, 2022
Submission Control Number: 254713
_ _
_ACETAZOLAMIDE _
_Page 2 of 12_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1 Pediatrics
..........................................................................................................4
1.2
Geriatrics...........................................................................................................4
2
CONTRAINDICATIONS
...................................................................................................4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
..............................................................4
4
DOSAGE AND
ADMINISTRATION...................................................................................4
4.2 Recommended Dose and Dosage Adjustment
........................................................4
5
OVERDOSAGE
...............................................................................................................5
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
...................................5
7
WARNINGS AND PRECAUTIONS
....................................................................................5
7.1 Special Populations
...............................................................................................5
7.1.2
Breast-feeding...........